Last updated: August 6, 2026
Bristol Myers Squibb (BMS) is one of the largest global biopharmaceutical companies, with leadership in oncology, immunology, cardiovascular medicine and hematology. Its 2023 revenue was $45.96 billion, led by Eliquis, Opdivo, Revlimid and Yervoy. The company’s central strategic problem is concentration: a small group of mature products generates most revenue, while key patent losses and therapeutic competition threaten the growth base.[1]
BMS is responding through business development, including the acquisitions of Karuna Therapeutics, Mirati Therapeutics and Turning Point Therapeutics, and through launches in schizophrenia, oncology, immunology and cardiovascular disease. The portfolio has substantial commercial depth, but its medium-term risk profile is defined by Eliquis and Opdivo patent exposure, Revlimid erosion, pricing pressure and competition from Merck, Johnson & Johnson, AbbVie, AstraZeneca, Pfizer and emerging biotechnology companies.
What is Bristol Myers Squibb's current market position?
BMS ranks among the leading global biopharmaceutical companies by prescription sales and has a particularly strong position in oncology and cardiovascular medicine. Its largest products have established physician adoption, broad regulatory approvals and extensive clinical data.
| Product |
Active ingredient |
Principal market |
2023 revenue |
Competitive position |
| Eliquis |
Apixaban |
Atrial fibrillation and venous thromboembolism |
Approximately $12.2 billion |
Leading direct oral anticoagulant |
| Opdivo |
Nivolumab |
Oncology |
Approximately $9.0 billion |
Leading PD-1 inhibitor, competing with Keytruda |
| Revlimid |
Lenalidomide |
Multiple myeloma and hematologic cancers |
Approximately $6.1 billion |
Mature franchise with generic erosion |
| Yervoy |
Ipilimumab |
Oncology |
Approximately $2.2 billion |
Established CTLA-4 immunotherapy |
| Orencia |
Abatacept |
Rheumatoid arthritis and autoimmune disease |
Approximately $3.3 billion |
Mature immunology product |
| Pomalyst/Imnovid |
Pomalidomide |
Multiple myeloma |
Approximately $3.0 billion |
Hematology franchise product |
| Breyanzi |
Lisocabtagene maraleucel |
B-cell malignancies |
Approximately $364 million |
Expanding CAR-T product |
| Abecma |
Idecabtagene vicleucel |
Multiple myeloma |
Approximately $355 million |
CAR-T product facing class competition |
Revenue data are based on BMS’ 2023 Form 10-K and company product disclosures.[1]
Eliquis remains the company’s largest commercial asset. Opdivo anchors the oncology platform, while Revlimid and related immunomodulatory drugs provide a durable hematology franchise. The portfolio’s strength comes from multiple indications, combination regimens and global distribution rather than reliance on a single therapeutic area.
How does Bristol Myers Squibb compare with its main competitors?
BMS is strongest where oncology and cardiovascular scale intersect. Its closest competitors differ by therapeutic focus and patent exposure.
| Competitor |
Principal competitive assets |
Competitive pressure on BMS |
| Merck & Co. |
Keytruda, Gardasil, oncology pipeline |
Direct competition with Opdivo across many tumor types |
| Johnson & Johnson |
Darzalex, Tremfya, Xarelto, Carvykti |
Hematology, immunology and anticoagulation competition |
| AbbVie |
Humira, Skyrizi, Rinvoq, Imbruvica |
Immunology and hematology competition |
| AstraZeneca |
Tagrisso, Imfinzi, Enhertu partnership, Farxiga |
Oncology and cardiovascular competition |
| Pfizer |
Ibrance, Eliquis partnership, Vyndaqel |
Cardiovascular and oncology overlap |
| Novartis |
Kisqali, Pluvicto, Leqvio |
Oncology and cardiovascular pipeline competition |
| Roche |
Tecentriq, Ocrevus, Hemlibra |
Oncology, immunology and hematology competition |
| Gilead Sciences |
Yescarta, Trodelvy, Biktarvy |
Cell therapy and oncology competition |
How does Opdivo compare with Keytruda?
Keytruda has a larger commercial position than Opdivo and broader penetration across tumor types. Merck has benefited from earlier and wider regulatory approvals, including lung cancer, breast cancer, gastrointestinal cancer and adjuvant settings.
Opdivo retains important advantages in renal cell carcinoma, esophageal cancer, hepatocellular carcinoma, melanoma, gastric cancer and combination therapy. The Opdivo-Yervoy combination has expanded BMS’ position in immuno-oncology, but Keytruda’s scale and clinical development productivity remain major competitive disadvantages for BMS.
The principal strategic issue is that PD-1 competition increasingly depends on combination regimens, biomarker segmentation, perioperative use and treatment sequencing. Stand-alone PD-1 differentiation is limited.
What patents protect Bristol Myers Squibb's major products?
BMS has a layered patent estate covering active ingredients, formulations, combination regimens, dosing schedules, manufacturing processes and specific methods of treatment. The practical value of each layer varies by product and by the scope of the asserted claims.
Eliquis patent estate
Eliquis is marketed by BMS and Pfizer. Its principal active ingredient is apixaban. The U.S. product has faced multiple Abbreviated New Drug Application filings and Paragraph IV patent challenges.
The principal U.S. composition patent, U.S. Patent No. 6,967,208, has a listed expiration in 2026. Pediatric exclusivity can extend relevant regulatory protection by six months, subject to the applicable FDA listing and exclusivity framework.[2] Later patents cover formulations and methods of use, but generic launch timing depends on which listed patents are challenged, litigation outcomes and settlement terms.
Eliquis has the highest near-term revenue exposure in the BMS portfolio. A rapid generic launch would affect both BMS and Pfizer, although market erosion would likely occur over several years rather than immediately reach full substitution.
Revlimid patent estate
Revlimid is based on lenalidomide and is protected by multiple composition, method-of-use and formulation patents. Generic competition began under settlement arrangements that permitted limited entry before the full loss of exclusivity date.
The Revlimid experience demonstrates the value of settlement agreements and restricted generic volumes. BMS and its predecessor Celgene preserved significant revenue after basic chemical patent expiration through later patents, risk-management requirements and negotiated generic launch dates.
Revlimid revenue is declining, but its remaining value comes from continued use in multiple myeloma, maintenance therapy and physician familiarity. The franchise also supports Pomalyst, which has separate patent and exclusivity considerations.
Opdivo patent estate
Opdivo is a biologic monoclonal antibody, so its U.S. regulatory protection is not managed through the small-molecule Orange Book in the same manner as Eliquis or Revlimid. Key protections arise from biologic exclusivity, composition and antibody patents, formulation patents, manufacturing know-how and method-of-use claims.
The principal commercial risk is not a conventional small-molecule generic launch. It is the eventual entry of biosimilars or follow-on products, combined with competition from other PD-1 and PD-L1 therapies. Patent disputes may focus on antibody structure, binding sites, dosing regimens, combination treatment and manufacturing processes.
What is the Orange Book status of BMS products?
The Orange Book is most relevant to BMS’ small-molecule products, including Eliquis, Revlimid, Pomalyst and Sprycel. It identifies approved drug products, therapeutic equivalence evaluations, listed patents and applicable pediatric exclusivity.[2]
Opdivo, Yervoy, Orencia, Breyanzi and Abecma are biologic products. Their principal regulatory protections are administered under the Public Health Service Act and FDA biologics licensing framework rather than through conventional Orange Book patent listings.
| Product |
U.S. regulatory category |
Orange Book relevance |
Main entry risk |
| Eliquis |
Small molecule |
High |
ANDA and Paragraph IV litigation |
| Revlimid |
Small molecule |
High |
Generic entry under settlements and later patents |
| Pomalyst |
Small molecule |
High |
ANDA challenges and patent expiry |
| Sprycel |
Small molecule |
High |
Generic competition |
| Opdivo |
Biologic |
Limited conventional relevance |
Biosimilar and follow-on competition |
| Yervoy |
Biologic |
Limited conventional relevance |
Biosimilar and oncology substitution |
| Orencia |
Biologic |
Limited conventional relevance |
Biosimilar competition |
| Breyanzi |
Cell therapy biologic |
Limited conventional relevance |
Manufacturing and follow-on cell therapy competition |
When does BMS lose exclusivity on Eliquis, Opdivo and Revlimid?
| Product |
Key protection issue |
Expected commercial pressure |
| Eliquis |
Core U.S. patent protection extends into 2026, with pediatric exclusivity potentially affecting timing |
Highest near-term revenue cliff |
| Revlimid |
Generic entry has already begun under negotiated restrictions |
Continuing annual erosion |
| Opdivo |
Patent and biologic exclusivity extend beyond early small-molecule losses, but timing varies by patent and indication |
Gradual biosimilar and therapeutic competition |
| Yervoy |
Biologic patents and exclusivity protect the product, with competition from newer immunotherapies |
Combination and class substitution |
| Orencia |
Mature biologic with biosimilar exposure |
Gradual payer-driven erosion |
Exact entry dates can differ between the earliest patent expiration, the end of FDA exclusivity, settlement-permitted entry dates and actual commercial launch. BMS’ annual reports identify material legal proceedings and risk factors, while FDA listings identify approved products and regulatory exclusivity.[1][2]
Which companies are challenging BMS patents?
Generic companies and large pharmaceutical manufacturers have challenged BMS-related patents through Paragraph IV certifications, ANDA litigation and settlement negotiations. The most relevant challengers for Eliquis and other small-molecule products include generic manufacturers such as Teva, Mylan/Viatris, Sandoz, Sun Pharma, Hetero, Zydus and Dr. Reddy’s, depending on the product and filing status.
For biologics, the competitive field includes companies developing biosimilars and next-generation therapies rather than conventional ANDA applicants. The timing of biosimilar entry depends on patent settlements, interchangeability strategy, manufacturing capacity and payer adoption.
Public litigation records should be reviewed on a product-by-product basis because a company may challenge one patent while accepting others, and a settlement may establish a confidential or staged launch date.
What patent litigation and settlement agreements affect BMS?
The most commercially important litigation concerns Eliquis and the company’s legacy Celgene products. BMS has used patent settlements to manage generic entry and preserve revenue while reducing the uncertainty associated with trial outcomes.
Settlement agreements can include:
- Delayed generic launch dates.
- Authorized generic arrangements.
- Volume restrictions.
- Covenants not to sue.
- Patent licenses.
- Product-specific launch rights.
- Terms affecting multiple generic manufacturers.
Revlimid settlements illustrate how several generic entrants can enter at different times and at different volumes. The arrangement reduces the likelihood of an immediate full market conversion but does not prevent long-term price erosion.
Eliquis litigation is more material because the product remains a large revenue contributor. The risk is concentrated in the U.S., where generic substitution can rapidly reduce net prices after launch.
What are BMS’ strongest strategic assets?
BMS has five principal competitive strengths.
Oncology scale and combination capability
The Opdivo and Yervoy franchises provide a large clinical-development platform. BMS can test combinations across tumor types and use established commercial infrastructure to support new indications.
Cardiovascular leadership
Eliquis has strong physician recognition, broad guideline support and extensive outcomes data. The product is embedded in atrial fibrillation and venous thromboembolism treatment pathways.
Hematology depth
Revlimid, Pomalyst, Abecma and Breyanzi give BMS exposure across multiple myeloma, lymphoma and other blood cancers. The portfolio includes conventional drugs and cell therapies, although commercial performance varies significantly by product.
Global regulatory and commercial infrastructure
BMS has the scale to conduct multinational trials, negotiate reimbursement and commercialize specialty medicines. This infrastructure reduces launch friction for products with differentiated clinical data.
Acquisition capacity
The acquisitions of Turning Point Therapeutics, Mirati Therapeutics and Karuna Therapeutics expanded BMS’ exposure to targeted oncology and central nervous system diseases. The KarXT asset, later branded Cobenfy, gives BMS an entry point into schizophrenia and a potential platform for additional neuropsychiatric indications.[3][4]
What weaknesses and generic entry risks face BMS?
BMS has a concentrated revenue base. Eliquis, Opdivo, Revlimid and related products account for a substantial portion of total sales. Loss of exclusivity on one major product can affect operating results, cash flow and investor valuation.
The company also faces:
- Keytruda’s greater scale in immuno-oncology.
- Declining Revlimid sales.
- High development costs for cell therapy.
- Manufacturing complexity for CAR-T products.
- Payer pressure in mature biologic categories.
- Dependence on clinical differentiation for pipeline assets.
- Integration and execution risk from acquisitions.
- Potential pricing pressure from U.S. drug-pricing reforms.
The Inflation Reduction Act creates a longer-term pricing risk for high-spend Medicare products. Eliquis is included among the first drugs selected for Medicare price negotiation, with negotiated prices scheduled to take effect in 2026.[5]
What formulations and manufacturing technologies are protected by BMS patents?
BMS protection extends beyond active ingredients. Relevant claim categories include:
- Oral tablet formulations.
- Crystalline and polymorphic forms.
- Stability and dissolution characteristics.
- Fixed-dose combinations.
- Dosing regimens.
- Patient-selection methods.
- Biomarker-defined oncology treatment.
- Antibody production and purification.
- Cell expansion, transduction and cryopreservation.
- Autologous cell-therapy manufacturing workflows.
Manufacturing barriers are especially important for Breyanzi and Abecma. Cell therapies require specialized collection, chain-of-identity controls, viral-vector or gene-modification processes, quality testing and release procedures. These barriers can delay competitors even when patent protection becomes less decisive.
For biologics, manufacturing know-how may remain commercially valuable after patent expiration because product consistency, scale, supply reliability and regulatory comparability affect market adoption.
What licensing deals and acquisitions support BMS growth?
BMS has relied heavily on acquisitions and external innovation. Key transactions include:
| Transaction |
Year |
Strategic purpose |
| Celgene acquisition |
2019 |
Added Revlimid, Pomalyst, Abraxane, Ozanimod rights and cell therapy assets |
| Turning Point Therapeutics acquisition |
2022 |
Added repotrectinib, later marketed as Augtyro |
| Mirati Therapeutics acquisition |
2023 |
Added Krazati and oncology pipeline assets |
| Karuna Therapeutics acquisition |
2024 |
Added KarXT, a late-stage schizophrenia and neuropsychiatry asset |
The Celgene transaction remains central to BMS’ current portfolio. It added significant revenue but also increased exposure to mature hematology products and patent cliffs. Karuna diversifies BMS away from oncology and cardiovascular medicine, while Mirati and Turning Point strengthen targeted oncology.
What is the FDA regulatory status of BMS’ growth products?
BMS’ growth strategy depends on converting recent approvals into broader labels and durable reimbursement.
Key products include:
- Opdivo, with multiple oncology indications.
- Breyanzi, an autologous CD19-directed CAR-T therapy.
- Abecma, a BCMA-directed CAR-T therapy.
- Augtyro, a ROS1 tyrosine kinase inhibitor.
- Krazati, a KRAS G12C inhibitor.
- Zeposia, an immunomodulatory therapy.
- Sotyktu, a TYK2 inhibitor for plaque psoriasis.
- Cobenfy, based on KarXT, for schizophrenia following the Karuna acquisition.
The commercial importance of these products depends on label expansion, treatment-line movement, manufacturing capacity and the ability to demonstrate superior outcomes or better tolerability against established standards.
How strong is the BMS patent estate?
BMS has a strong but uneven patent estate. Its strongest protections combine composition patents with multiple indications, formulation claims, manufacturing know-how and high clinical switching costs. Its weakest position occurs when products are mature, chemically simple, heavily reimbursed and exposed to multiple generic manufacturers.
| Dimension |
Assessment |
| Eliquis |
Strong commercial franchise, concentrated patent-cliff exposure |
| Opdivo |
Strong biologic and clinical estate, but intense therapeutic competition |
| Revlimid |
Historically strong layered estate, now in managed erosion |
| CAR-T products |
High manufacturing barriers, complex regulatory pathway |
| New targeted therapies |
Dependent on label expansion and resistance management |
| Neuropsychiatry pipeline |
Diversifying opportunity with execution and adoption risk |
Patent strength should be assessed by claim breadth, remaining term, validity risk, infringement evidence, regulatory exclusivity, settlement terms and the number of commercially viable substitutes. Patent count alone is not a reliable measure of protection.
What generic launch scenarios exist for BMS products?
The most likely pattern is staggered erosion rather than an immediate collapse.
Eliquis
A first generic launch could trigger rapid price reductions, followed by additional entrants and increased payer substitution. BMS and Pfizer may retain branded demand through formulary positioning, physician familiarity and patients who remain on the branded product.
Revlimid
The market is already in a staged generic-entry cycle. Revenue should continue to decline as additional volume becomes available and generic discounts deepen.
Opdivo and other biologics
Biosimilar or follow-on entry is likely to be slower than conventional ANDA substitution. Physician confidence, hospital protocols, interchangeability decisions, manufacturing capacity and payer policy will determine adoption.
What revenue exposure does BMS face?
BMS’ exposure is highest in products with large sales, narrow remaining protection and readily substitutable competitors.
| Risk driver |
Revenue implication |
| Eliquis patent loss |
Potentially the largest single-product erosion event |
| Revlimid generic expansion |
Persistent decline in hematology revenue |
| Opdivo competition |
Slower growth and pressure on combination pricing |
| CAR-T manufacturing constraints |
Limits near-term revenue conversion |
| New product launches |
Required to offset mature-product losses |
| Medicare negotiation |
Potential net-price pressure on selected products |
BMS’ financial resilience depends on the pace of new-product growth, cost control, business-development discipline and the ability to sustain Opdivo and Eliquis demand during the transition period.
Key Takeaways
- BMS is a leading oncology, hematology and cardiovascular company with 2023 revenue of approximately $46 billion.
- Eliquis is the most important near-term patent and revenue exposure, with core U.S. protection extending into 2026 and potential pediatric exclusivity effects.
- Revlimid is already experiencing staged generic erosion under settlement-based entry arrangements.
- Opdivo remains a major oncology asset but faces direct competition from Merck’s Keytruda and broader immuno-oncology competition.
- BMS’ biologic and cell-therapy products rely on patents, regulatory exclusivity, manufacturing know-how and clinical adoption barriers.
- Acquisitions of Karuna, Mirati and Turning Point are intended to replace mature-product revenue and diversify the portfolio.
- The company’s patent estate is commercially strong but concentrated, with the highest risk tied to Eliquis and legacy Celgene products.
- Medicare price negotiation adds a separate pricing risk for high-spend products.
FAQs
What is BMS’ largest product by revenue?
Eliquis is BMS’ largest product by revenue. It is marketed with Pfizer for stroke prevention in atrial fibrillation and treatment or prevention of venous thromboembolism.
Does Opdivo have biosimilar competition?
Opdivo does not face conventional generic competition. Future competitors would likely enter through the biosimilar or follow-on biologic pathway, subject to patent, regulatory and manufacturing requirements.
Is Revlimid still commercially important to BMS?
Yes. Revlimid revenue is declining because of generic entry, but it remains strategically important because of its role in multiple myeloma treatment and its relationship to BMS’ broader hematology portfolio.
Which BMS acquisition has the greatest non-oncology significance?
The Karuna acquisition has the greatest non-oncology significance because it adds a late-stage schizophrenia product and expands BMS into central nervous system medicine.
What is the main investment risk in the BMS portfolio?
The primary risk is the concentration of revenue in mature products, especially Eliquis, Opdivo and legacy Celgene assets. The company must replace declining sales with new launches, label expansions and successful acquired products.
References
- Bristol Myers Squibb. (2024). 2023 annual report and Form 10-K. https://www.bms.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- Bristol Myers Squibb. (2023). Bristol Myers Squibb to acquire Mirati Therapeutics. https://www.bms.com
- Bristol Myers Squibb. (2024). Bristol Myers Squibb completes acquisition of Karuna Therapeutics. https://www.bms.com
- U.S. Department of Health and Human Services. (2023). Medicare drug price negotiation program: Selected drugs for initial price applicability year 2026. https://www.cms.gov
